Pro-substrates for live cell applications

US9927430B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9927430-B2
Application numberUS-201514608910-A
CountryUS
Kind codeB2
Filing dateJan 29, 2015
Priority dateJan 29, 2014
Publication dateMar 27, 2018
Grant dateMar 27, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided are pro-substrates useful in assays of living cells. The pro-substrates can be used to detect the presence or absence of enzymes, such as luciferase, in living cells. The pro-substrates can be coelenterazine derivatives or analogs.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of formula (I), or a salt thereof, wherein, R A is selected from the group consisting of —(CR 1 R 2 ) m —N(R 3 )C(O)R 4 , —(CR 5 R 6 ) m —SO 3 R 7 , and —(CR 10 R 11 ) m —CO 2 R 12 , wherein m at each occurrence is independently 2, 3, or 4; R 1 , R 2 , R 3 , R 5 , R 6 , R 7 , R 10 , R 11 , and R 12 at each occurrence are independently hydrogen or C 1 -C 4 alkyl; R 4 is C 1 -C 4 alkyl, C 1 -C 4 alkoxy, carboxy-C 1 -C 4 alkoxy-C 1 -C 4 alkyl, phenyl optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from the group consisting of halogen, C 1 -C 4 alkoxy, and C 1 -C 4 haloakyl,  wherein R 41 , R 42 , and R 44 at each occurrence are each independently carboxy-C 1 -C 4 alkyl; R 43 and R 45 are each independently selected from the group consisting of hydrogen, —C(O)alkyl, and x and y are each independently an integer selected from 1 to 20; R B is —(CR 46 R 47 ) t —NR 48 R 49 , wherein t is 1, 2, 3, 4, 5, 6, 7, or 8 R 46 and R 47 at each occurrence are independently hydrogen or C 1 -C 4 alkyl; R 48 and R 49 at each occurrence are independently hydrogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aminoalkyl, alkylaminoalkyl, di(alkyl)aminoalkyl, cyanoalkyl, —(CR 50 R 51 ) z —OC(O)R 52 ; or R 48 and R 49 together with the nitrogen atom to which they are attached form a heterocyclyl, wherein said heterocyclyl is unsubstituted or substituted with 1, 2, 3, 4, 5 or 6 substituents independently selected from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 1 -C 4 alkynyl, —NO 2 , —CN, halogen, oxo, —OR 96 , —OC(O)R 97 , and —C(O)R 116 , wherein R 50 and R 51 at each occurrence are independently hydrogen or C 1 -C 4 alkyl; R 52 , R 96 , R 97 , and R 116 at each occurrence are independently hydrogen, C 1 -C 6 alkyl, or aryl; z is 1, 2, 3, or 4; R C is —(CH) 0-3 -T or C 1-5 alkyl; wherein T is aryl, heteroaryl, or cycloalkyl, wherein said aryl, heteroaryl, and cycloalkyl are each independently unsubstituted or substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aminoalkyl, alkylaminoalkyl, di(alkylaminoalkyl), cyanoalkyl, alkoxy, haloalkoxy, cyano, hydroxy, amino, alkylamino, and di(alkyl)amino; R D is hydrogen, C 1 -C 4 alkyl, benzyl, or C 3 -C 6 cycloalkyl; R E is hydrogen, hydroxy, alkoxy, amino, alkylamino, di(alkyl)amino, —OC(O)alkyl, or —OCH 2 OC(O)alkyl; wherein the dash bonds together indicate the presence of an optional 6-membered ring in the compound of formula (I), wherein the optional ring is saturated or unsaturated; and wherein the optional 6-membered ring is absent. 2. The compound of claim 1 , or a salt thereof, wherein R A is —(CR 1 R 2 ) m —N(R 3 )C(O)R 4 , wherein m, R 1 , R 2 , R 3 , and R 4 are as defined in claim 1 . 3. The compound of claim 1 , or a salt thereof, wherein R A is selected from the group consisting of: 4. The compound of claim 1 , or a salt thereof wherein R B is selected from the group consisting of: 5. The compound of claim 1 , or a salt thereof wherein R C is furylmethyl or benzyl, R D is benzyl, or R E is hydrogen. 6. The compound of claim 1 , having formula (I-iv), or a salt thereof, wherein R 200 is aryl or heteroaryl, each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aminoalkyl, cyanoalkyl, alkoxy, haloalkoxy, cyano, hydroxy, and amino; and R A , and R B are as defined in claim 1 . 7. The compound of claim 1 , having formula (I-x), or a salt thereof, wherein s is 1 or 2; R 201 is aryl or heteroaryl, each optionally substituted with 1, 2, or 3 substituents independently selected from the group consisting of halogen, alkyl, haloalkyl, hydroxyalkyl, alkoxyalkyl, haloalkoxyalkyl, aminoalkyl, cyanoalkyl, alkoxy, haloalkoxy, cyano, hydroxy, and amino; and R A is as defined in claim 1 . 8. The compound of claim 2 , having formula (I-xvii), or a salt thereof, wherein q is 1 or 2; s is 1 or 2. 9. The compound of claim 1 , or a salt thereof, selected from the group consisting of: or a salt thereof. 10. The compound of claim 1 , or a salt thereof, wherein R A is wherein R 41 , R 42 , R 43 , R 44 , R 45 , x, and y are as defined in claim 1 ; and R B is 11. A composition comprising a mixture of a compound of formula (I) according to claim 1 , or a salt thereof, and at least one compound of formula (II), wherein R C , R D , and R E in formula (II) are as defined in claim 1 ; and wherein the dash bonds of formula (II) indicates an optional 6-membered ring, which is absent. 12. The composition according to claim 11 , wherein the compound of formula (II) is selected from the group consisting of (II-i), (II-ii), (II-iii), (II-iv), and (II-v), or a combination thereof, 13. A method to detect an interaction between a first protein and a second protein in a sample, the method comprising: (a) contacting a sample with the compound of claim 1 , or a salt thereof, wherein the sample comprises: (i) a first polynucleotide encoding a first fusion protein, wherein the first fusio

Assignees

Inventors

Classifications

  • Ortho-condensed systems · CPC title

  • with the first amino acid being acidic · CPC title

  • G01N33/542Primary

    with steric inhibition or signal modification, e.g. fluorescent quenching · CPC title

  • involving luciferase · CPC title

  • Methods of identifying protein-protein interactions in protein mixtures · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9927430B2 cover?
Provided are pro-substrates useful in assays of living cells. The pro-substrates can be used to detect the presence or absence of enzymes, such as luciferase, in living cells. The pro-substrates can be coelenterazine derivatives or analogs.
Who is the assignee on this patent?
Promega Corp
What technology area does this patent fall under?
Primary CPC classification G01N33/542. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Mar 27 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).